ReviewCureus2025
The Effect of Omega-3 on Mitigating Exercise-Induced Muscle Damage.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exercise-induced muscle damage (EIMD) refers to muscle injuries following exercises involving repetitive eccentric muscle contractions. The resultant inflammation and muscle protein leakage into the circulation lead to muscle pain and strength deficit, compromising athletic performance. This narrative review summarizes the current evidence on the effect and mechanism of omega-3 polyunsaturated fatty acids (n-3 PUFA) in potentially mitigating EIMD. Several studies suggested n-3 PUFA's role in alleviating delayed-onset muscle soreness, particularly in untrained individuals and those receiving higher doses of continuous supplementation. However, its impact on muscle strength attenuation and the reduction of performance post-exercise remains inconclusive. Also unclear are n-3 PUFA's effects on the reduction of circulating pro-inflammatory substances and muscle proteins. One of the possible mechanisms is its anti-inflammatory property, which involves its ability to incorporate into cell membranes and displace prostaglandin precursor. n-3 PUFA also decreases cyclooxygenase production and can be converted into specialized pro-resolving mediators (SPMs), further reducing inflammation. Moreover, n-3 PUFA's incorporation into cell membranes alters cell membrane properties, diminishing protein release during muscle breakdown. n-3 PUFA exhibits analgesic effects through SPM-induced modulation of receptors and ion channels, reducing both peripheral and central sensitization. n-3 PUFA also diminishes mitochondrial free radical production and accelerates nerve conduction, thereby improving voluntary muscle activation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.